A Study to Evaluate the Effectiveness & Safety of Dysport® for

Status Recruiting

Clinical Trial Summary

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or dose "B" of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06047444
Study type	Interventional
Source	Ipsen
Contact	Ipsen Clinical Study Enquiries
Phone	See e mail
Email	clinical.trials@ipsen.com
Status	Recruiting
Phase	Phase 3
Start date	October 12, 2023
Completion date	December 21, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05720819` - Biofeedback-VR for Treatment of Chronic Migraine	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Completed	`NCT02514148` - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients	N/A
Enrolling by invitation	`NCT02291380` - A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine	Phase 3
Withdrawn	`NCT02122744` - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine	N/A
Completed	`NCT02122237` - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial	Phase 3
Recruiting	`NCT02202486` - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	N/A
Completed	`NCT01709708` - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine	Phase 4
Completed	`NCT01741246` - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging	N/A
Completed	`NCT01090050` - Treximet in the Treatment of Chronic Migraine	Phase 4
Recruiting	`NCT03507400` - Introvision for Migraine and Headaches	N/A
Completed	`NCT04161807` - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine	N/A
Completed	`NCT03175263` - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain	N/A
Withdrawn	`NCT04353505` - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache	Phase 1
Completed	`NCT01700387` - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency	Phase 4
Completed	`NCT01667250` - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine	N/A
Not yet recruiting	`NCT01135784` - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache	Phase 2
Completed	`NCT00772031` - NINDS CRC Chronic Migraine Treatment Trial	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults — C-BEOND

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms